Skip to main content

Advertisement

Table 1 Baseline sleep impairment

From: Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies

Scale ASTERIA I ASTERIA II GLACIAL
Placebo Omalizumab 75 mg Omalizumab 150 mg Omalizumab 300 mg Placebo Omalizumab 75 mg Omalizumab 150 mg Omalizumab 300 mg Placebo Omalizumab 300 mg
MOS-Sleep Scale, SPI-II, n 80 77 80 81 79 82 82 79 83 252
 Mean (SD)a 47.8 (19.8) 48.4 (17.8) 49.2 (21.2) 47.4 (19.3) 47.4 (18.1) 48.0 (18.6) 48.5 (18.6) 47.8 (17.8) 47.9 (18.6) 49.1 (18.9)
UPDD Weekly Sleep Interference Score, n 80 77 80 81 79 82 82 79 83 252
 Mean (SD) 12.6 (4.8) 12.2 (5.3) 12.1 (5.2) 12.2 (4.5) 12.1 (4.5) 11.8 (5.4) 11.4 (5.6) 11.6 (4.3) 11.2 (5.2) 11.9 (4.8)
CU-Q2oL Sleep Problems domain, n 80 77 80 81 79 82 82 79 83 252
 Mean (SD)b 48.7 (23.6) 46.8 (22.7) 48.2 (25.2) 49.3 (22.9) 46.6 (19.9) 45.1 (22.6) 46.4 (23.7) 49.4 (21.1) 46.5 (21.8) 46.4 (21.5)
  1. CU-Q 2 oL Chronic Urticaria Quality of Life Questionnaire, MOS-Sleep Scale Medical Outcomes Study Sleep Scale, SPI-II Sleep Problem Index II, UPDD Urticaria Patient Daily Diary
  2. aNumber of patients: ASTERIA I: omalizumab 75 mg, n = 76; ASTERIA II: placebo, n = 78; GLACIAL: placebo, n = 82; omalizumab 300 mg, n = 250
  3. bNumber of patients: ASTERIA I: placebo, n = 63; omalizumab 75 mg, n = 59; omalizumab 150 mg, n = 63; omalizumab 300 mg, n = 61; ASTERIA II: placebo, n = 69; omalizumab 75 mg, n = 70; omalizumab 150 mg, n = 70; omalizumab 300 mg, n = 71; GLACIAL: placebo, n = 79; omalizumab 300 mg, n = 243